Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Creo is a synthetic biology company focused on the sustainable production of cannabinoids through advanced fermentation technology. By utilizing proprietary yeast strains, the company produces high-purity, rare cannabinoids such as CBG and CBGA without the need for traditional cannabis cultivation. Their process offers a consistent, scalable, and environmentally friendly alternative to plant-derived extraction, targeting applications in the pharmaceutical, wellness, and consumer goods sectors. Creo aims to enable the widespread use of cannabinoids by providing reliable, high-quality ingredients for therapeutic and commercial development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Creo SG.